SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
Targeted inhibition of the ERK-MAPK pathway is challenged by the development of resistance and toxicity. Here, the authors show that SHOC2 genetic inhibition impairs lung tumour development and improves MEK inhibitor efficacy in RAS- and EGFR-mutant cells.
Guardado en:
Autores principales: | Greg G. Jones, Isabel Boned del Río, Sibel Sari, Aysen Sekerim, Lucy C. Young, Nicole Hartig, Itziar Areso Zubiaur, Mona A. El-Bahrawy, Rob E. Hynds, Winnie Lei, Miriam Molina-Arcas, Julian Downward, Pablo Rodriguez-Viciana |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/63c728d50eef448aa2fdb9117a059704 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Ting Jin, et al.
Publicado: (2017) -
KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
por: Timothy H. Tran, et al.
Publicado: (2021) -
REG3A/REG3B promotes acinar to ductal metaplasia through binding to EXTL3 and activating the RAS-RAF-MEK-ERK signaling pathway
por: Huairong Zhang, et al.
Publicado: (2021) -
An engineered protein antagonist of K-Ras/B-Raf interaction
por: Monique J. Kauke, et al.
Publicado: (2017) -
The effect of arrestin conformation on the recruitment of c-Raf1, MEK1, and ERK1/2 activation.
por: Sergio Coffa, et al.
Publicado: (2011)